Treatment of Advanced Renal Cell Carcinoma With Quinacrine
Status:
Withdrawn
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The overall response to standard therapies and to the newer antiangiogenesis therapies is not
curative, and treatment-associated toxicities may be severe. Therefore, continued evaluation
of therapies, with different mechanisms of action, is needed for patients with metastatic
RCC.